It's not entirely clear why medicine has been so slow to build on Anderson' s early success. The National Institutes of Health budget office estimates it will spend $ 432 million on gene-therapy research in 2005, and there is no shortage of promising leads. The therapeutic genes are usually delivered through viruses that don' t cause human disease. "The virus is sort of like a Trojan horse," says Ronald Crystal of New York Presbyterian/Weill Cornell Medical College. "The cargo is the gene. "
At the University of Pennsylvania's Abramson Cancer Center, immunologist Carl June recently treated HIV pa tients with a gene intended to help their cells resist the infection. At Cornell University, researchers are pursuing gene-based therapies for Parkinson's disease and a rare hereditary disorder that destroys children' s brain cells. At Stanford University and the Children' s Hospital of Philadelphia, researchers are trying to figure out how to help patients with hemophilia who today must inject themselves with expensive clotting drugs for life. Animal experiments have shown great promise.
But somehow, things get lost in the translation from laboratory to patient. In human trials of the hemophilia treatment, patients show a response at first, but it fades over time. And the field has still not recovered from the setback it suffered in 1999, when Jesse Gelsinger, an 18-year-old with a rare metabolic disorder, died after receiving an experimental gene therapy at the University of Pennsylvania. Some experts worry that the field will be tarnished further if the next people to benefit are not patients but athletes seeking an edge. This summer, researchers at the Salk Institute in San Diego said they had created a "marathon mouse" by implanting a gene that enhances running ability; already, officials at the World Anti-Doping Agency are preparing to test athletes for signs of "gene doping". But the principle is the same, whether you're trying to help a healthy runner run faster or allow a muscular-dystro-phy patient to walk. "Everybody recognizes that gene therapy is a very good idea," says Crystal. "And eventually it's going to work. "
The case of Ashanthi Desilva is mentioned in the text to
A.show the promise of gene-therapy
B.give an example of modem treatment for fatal diseases
C.introduce the achievement of Anderson and his team
D.explain how gene-based treatment works
第1题
有关上肢血压测量法,下述哪项不妥
A. 测量前让患者休息15min
B. 患者坐位时肱动脉平第4肋软骨
C. 将患者的衣袖卷至肩部
D. 袖带平整缠在上臂下段
E. 袖带松紧度以能放入一指为宜
第2题
有关上肢血压测量法,下述哪项不妥
A.测量前让患者休息15min
B.患者坐位时肱动脉平第4肋软骨
C.将患者的衣袖卷至肩部
D.袖带平整缠在上臂下段
E.袖带松紧度以能放入一指为宜
第3题
上肢血压测量法,下述哪项不妥()。
A.测量前让病人休息15min
B.病人坐位时肱动脉平第四肋软骨
C.将病人的衣袖卷至肩部
D.袖带平整缠在上臂下部
E.袖带松紧度以能放入一指为宜
第4题
有关上肢血压测量法,下述哪项不妥
A.测量前让患者休息15min
B.患者坐位时肱动脉平第4肋软骨
C.将患者的衣袖卷至肩部
D.袖带平整缠在上臂下段
E.袖带松紧度以能放入一指为宜
第5题
有关上肢血压测量法,下述哪项不妥
A.测量前让患者休息15分钟
B.患者坐位时肱动脉平第4肋软骨
C.将患者的衣袖卷至肩部
D.袖带平整缠在上臂下段
E.袖带松紧度以能放入一指为宜
第6题
上肢血压测量法,下述哪项不妥()。【历年考试真题】
A.测量前让病人休息15分钟
B.病人坐位时肱动脉平第四肋软骨
C.将病人的衣袖卷至肩部
D.袖带平整缠在上臂下部
E.袖带松紧度以能放入一指为宜
第8题
使血压值偏高的因素包括
A. 水银不足
B. 衣袖束缚太紧
C. 测量成人的袖带用于测儿童的血压
D. 袖带缠得太紧
E. 袖带缠得太松
为了保护您的账号安全,请在“上学吧”公众号进行验证,点击“官网服务”-“账号验证”后输入验证码“”完成验证,验证成功后方可继续查看答案!